Impax Asset Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.05M | Hold |
4,134
| – | – | 0.01% | 257 |
|
|
2026
Q1 | $1.85M | Sell |
4,134
-488
| -11% | -$228K | 0.01% | 253 |
|
|
2025
Q4 | $2.1M | Hold |
4,622
| – | – | 0.01% | 232 |
|
|
2025
Q3 | $1.81M | Hold |
4,622
| – | – | 0.01% | 224 |
|
|
2025
Q2 | $2.06M | Sell |
4,622
-2,377
| -34% | -$1.1M | 0.01% | 230 |
|
|
2025
Q1 | $3.39M | Buy |
6,999
+75
| +1% | +$35K | 0.02% | 221 |
|
|
2024
Q4 | $2.79M | Sell |
6,924
-509
| -7% | -$236K | 0.01% | 238 |
|
|
2024
Q3 | $3.46M | Sell |
7,433
-45,963
| -86% | -$22.1M | 0.01% | 234 |
|
|
2024
Q2 | $25M | Sell |
53,396
-14,362
| -21% | -$6.23M | 0.1% | 116 |
|
|
2024
Q1 | $28.3M | Sell |
67,758
-16,555
| -20% | -$7M | 0.11% | 122 |
|
|
2023
Q4 | $34.3M | Sell |
84,313
-473,825
| -85% | -$175M | 0.14% | 114 |
|
|
2023
Q3 | $194M | Sell |
558,138
-25,782
| -4% | -$9.02M | 0.87% | 39 |
|
|
2023
Q2 | $205M | Sell |
583,920
-178,427
| -23% | -$60.1M | 0.82% | 43 |
|
|
2023
Q1 | $240M | Sell |
762,347
-1,664
| -0.2% | -$499K | 1% | 35 |
|
|
2022
Q4 | $220M | Buy |
764,011
+66,278
| +9% | +$20.2M | 0.99% | 37 |
|
|
2022
Q3 | $202M | Sell |
697,733
-23,201
| -3% | -$6.68M | 1.04% | 33 |
|
|
2022
Q2 | $203M | Sell |
720,934
-139,738
| -16% | -$37.4M | 0.99% | 35 |
|
|
2022
Q1 | $225M | Sell |
860,672
-172,183
| -17% | -$40.9M | 0.93% | 39 |
|
|
2021
Q4 | $227M | Sell |
1,032,855
-41,881
| -4% | -$8.14M | 0.83% | 47 |
|
|
2021
Q3 | $195M | Buy |
1,074,736
+319,209
| +42% | +$62.3M | 0.8% | 49 |
|
|
2021
Q2 | $152M | Buy |
755,527
+666,559
| +749% | +$139M | 0.67% | 55 |
|
|
2021
Q1 | $19.1M | Buy |
88,968
+13,396
| +18% | +$2.94M | 0.1% | 109 |
|
|
2020
Q4 | $17.9M | Buy |
75,572
+10,381
| +16% | +$2.38M | 0.11% | 100 |
|
|
2020
Q3 | $17.7M | Buy |
65,191
+18,641
| +40% | +$5.14M | 0.16% | 91 |
|
|
2020
Q2 | $13.5M | Sell |
46,550
-6,121
| -12% | -$1.66M | 0.14% | 102 |
|
|
2020
Q1 | $12.5M | Buy |
52,671
+7,880
| +18% | +$1.81M | 0.17% | 101 |
|
|
2019
Q4 | $9.81M | Buy |
44,791
+468
| +1% | +$94.7K | 0.11% | 117 |
|
|
2019
Q3 | $7.51M | Buy |
44,323
+39,709
| +861% | +$7.02M | 0.1% | 137 |
|
|
2019
Q2 | $846K | Buy |
4,614
+444
| +11% | +$77.6K | 0.01% | 204 |
|
|
2019
Q1 | $767K | Buy |
4,170
+703
| +20% | +$130K | 0.01% | 235 |
|
|
2018
Q4 | $575K | Buy |
3,467
+66
| +2% | +$11.4K | 0.01% | 222 |
|
|
2018
Q3 | $656K | Buy |
+3,401
| New | +$606K | 0.01% | 230 |
|
Other funds holding VRTX
Impax Asset Management Group's VRTX Position: Q2 2026 in Review
Impax Asset Management Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,134 shares worth $2.05M. The position accounts for 0.01% of the portfolio, ranked #257.
Impax Asset Management Group first reported a position in VRTX in Q3 2018 and has held it in 32 quarters since. The position peaked at $240M in Q1 2023. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Impax Asset Management Group held 4,134 shares of Vertex Pharmaceuticals worth $2.05M as of Q2 2026.
- Impax Asset Management Group left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up 0.01% of Impax Asset Management Group's portfolio in Q2 2026, its #257 holding.
- Impax Asset Management Group first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Impax Asset Management Group's Vertex Pharmaceuticals position peaked at $240M in Q1 2023.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.